L-DOPA sodium

L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research[1][2][3].

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

Human Endogenous Metabolite

L-DOPA sodium (20 mg/kg; orally) reduces Rotenone-induced motor dysfunction[3]. L-DOPA sodium (0-100 mg/kg; orally) reverses tactile, cold and heat allodynia in neuropathic rat without any side effect in sprague-Dawley rats[4]. Animal Model: C57BL/6J mice (7-week-old)[3] Dosage: 20 mg/kg Administration: Orally Result: Reduced Rotenone-induced motor dysfunction. Animal Model: Sprague-Dawley rats[4] Dosage: 10, 30, 50, 70, and 100 mg/kg Administration: Orally Result: Reverses tactile, cold and heat allodynia in neuropathic rat without any side effect.

[1]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.

[2]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.

[3]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237.

[4]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.